Literature DB >> 33910954

Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity.

Samuel J Resnick1,2, Sho Iketani3,4, Seo Jung Hong1, Arie Zask5, Hengrui Liu6, Sungsoo Kim1, Schuyler Melore1, Fang-Yu Lin7, Manoj S Nair3, Yaoxing Huang3, Sumin Lee6, Nicholas E S Tay6, Tomislav Rovis6, Hee Won Yang1, Li Xing7, Brent R Stockwell5,6, David D Ho3, Alejandro Chavez1.   

Abstract

We describe a mammalian cell-based assay to identify coronavirus 3CL protease (3CLpro) inhibitors. This assay is based on rescuing protease-mediated cytotoxicity and does not require live virus. By enabling the facile testing of compounds across a range of 15 distantly related coronavirus 3CLpro enzymes, we identified compounds with broad 3CLpro-inhibitory activity. We also adapted the assay for use in compound screening and in doing so uncovered additional severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3CLpro inhibitors. We observed strong concordance between data emerging from this assay and those obtained from live-virus testing. The reported approach democratizes the testing of 3CLpro inhibitors by developing a simplified method for identifying coronavirus 3CLpro inhibitors that can be used by the majority of laboratories, rather than the few with extensive biosafety infrastructure. We identified two lead compounds, GC376 and compound 4, with broad activity against all 3CL proteases tested, including 3CLpro enzymes from understudied zoonotic coronaviruses. IMPORTANCE Multiple coronavirus pandemics have occurred over the last 2 decades. This has highlighted a need to be proactive in the development of therapeutics that can be readily deployed in the case of future coronavirus pandemics. We developed and validated a simplified cell-based assay for the identification of chemical inhibitors of 3CL proteases encoded by a wide range of coronaviruses. This assay is reporter free, does not require specialized biocontainment, and is optimized for performance in high-throughput screening. By testing reported 3CL protease inhibitors against a large collection of 3CL proteases with variable sequence similarity, we identified compounds with broad activity against 3CL proteases and uncovered structural insights into features that contribute to their broad activity. Furthermore, we demonstrated that this assay is suitable for identifying chemical inhibitors of proteases from families other than 3CL proteases.

Entities:  

Keywords:  3CL protease; COVID-19; SARS-CoV-2; antiviral drugs; cell-based assay; coronavirus; protease inhibitors; protease-mediated cytotoxicity; zoonotic coronaviruses

Mesh:

Substances:

Year:  2021        PMID: 33910954      PMCID: PMC8223961          DOI: 10.1128/JVI.02374-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism.

Authors:  Changkang Huang; Ping Wei; Keqiang Fan; Ying Liu; Luhua Lai
Journal:  Biochemistry       Date:  2004-04-20       Impact factor: 3.162

2.  In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.

Authors:  S L Binford; P T Weady; F Maldonado; M A Brothers; D A Matthews; A K Patick
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191

3.  The consequences of a lab escape of a potential pandemic pathogen.

Authors:  Lynn C Klotz; Edward J Sylvester
Journal:  Front Public Health       Date:  2014-08-11

Review 4.  Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections.

Authors:  Helmut Sies; Michael J Parnham
Journal:  Free Radic Biol Med       Date:  2020-06-26       Impact factor: 7.376

5.  Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2.

Authors:  Ewelina Weglarz-Tomczak; Jakub M Tomczak; Michał Talma; Małgorzata Burda-Grabowska; Mirosław Giurg; Stanley Brul
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379

6.  A role for selenium-dependent GPX1 in SARS-CoV-2 virulence.

Authors:  Lucia A Seale; Daniel J Torres; Marla J Berry; Matthew W Pitts
Journal:  Am J Clin Nutr       Date:  2020-08-01       Impact factor: 8.472

7.  High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase.

Authors:  Jan E Blanchard; Nadine H Elowe; Carly Huitema; Pascal D Fortin; Jonathan D Cechetto; Lindsay D Eltis; Eric D Brown
Journal:  Chem Biol       Date:  2004-10

8.  Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CLpro Reporter Assay.

Authors:  Heather M Froggatt; Brook E Heaton; Nicholas S Heaton
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

9.  Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection.

Authors:  Jin Wei; Mia Madel Alfajaro; Peter C DeWeirdt; Ruth E Hanna; William J Lu-Culligan; Wesley L Cai; Madison S Strine; Shang-Min Zhang; Vincent R Graziano; Cameron O Schmitz; Jennifer S Chen; Madeleine C Mankowski; Renata B Filler; Neal G Ravindra; Victor Gasque; Fernando J de Miguel; Ajinkya Patil; Huacui Chen; Kasopefoluwa Y Oguntuyo; Laura Abriola; Yulia V Surovtseva; Robert C Orchard; Benhur Lee; Brett D Lindenbach; Katerina Politi; David van Dijk; Cigall Kadoch; Matthew D Simon; Qin Yan; John G Doench; Craig B Wilen
Journal:  Cell       Date:  2020-10-20       Impact factor: 66.850

View more
  9 in total

1.  Engineering and Characterization of Avian Coronavirus Mutants Expressing Fluorescent Reporter Proteins from the Replicase Gene.

Authors:  Na Xing; Zhisheng Wang; Jichun Wang; Mariana Nascimento; Anan Jongkaewwattana; Jakob Trimpert; Nikolaus Osterrieder; Dusan Kunec
Journal:  J Virol       Date:  2022-07-05       Impact factor: 6.549

2.  Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells.

Authors:  Rémi Planès; Miriam Pinilla; Karin Santoni; Audrey Hessel; Charlotte Passemar; Kenneth Lay; Perrine Paillette; Ana-Luiza Chaves Valadão; Kim Samirah Robinson; Paul Bastard; Nathaniel Lam; Ricardo Fadrique; Ida Rossi; David Pericat; Salimata Bagayoko; Stephen Adonai Leon-Icaza; Yoann Rombouts; Eric Perouzel; Michèle Tiraby; Qian Zhang; Pietro Cicuta; Emmanuelle Jouanguy; Olivier Neyrolles; Clare E Bryant; Andres R Floto; Caroline Goujon; Franklin Zhong Lei; Guillaume Martin-Blondel; Stein Silva; Jean-Laurent Casanova; Céline Cougoule; Bruno Reversade; Julien Marcoux; Emmanuel Ravet; Etienne Meunier
Journal:  Mol Cell       Date:  2022-05-16       Impact factor: 19.328

3.  Human Superantibodies to 3CLpro Inhibit Replication of SARS-CoV-2 across Variants.

Authors:  Kittirat Glab-Ampai; Kanasap Kaewchim; Thanatsaran Saenlom; Watayagorn Thepsawat; Kodchakorn Mahasongkram; Nitat Sookrung; Wanpen Chaicumpa; Monrat Chulanetra
Journal:  Int J Mol Sci       Date:  2022-06-13       Impact factor: 6.208

4.  A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.

Authors:  K Y Chen; T Krischuns; L Ortega Varga; E Harigua-Souiai; S Paisant; A Zettor; J Chiaravalli; D Courtney; A O'Brien; S C Baker; C Isel; F Agou; Y Jacob; A Blondel; N Naffakh
Journal:  bioRxiv       Date:  2021-12-21

5.  Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay.

Authors:  Wenyue Cao; Chia-Chuan Dean Cho; Zhi Zachary Geng; Namir Shaabani; Xinyu R Ma; Erol C Vatansever; Yugendar R Alugubelli; Yuying Ma; Sankar P Chaki; William H Ellenburg; Kai S Yang; Yuchen Qiao; Robert Allen; Benjamin W Neuman; Henry Ji; Shiqing Xu; Wenshe Ray Liu
Journal:  ACS Cent Sci       Date:  2022-02-02       Impact factor: 14.553

6.  COVID 19, Paxlovid and the lesson from rare genetic diseases with naturally occurring protection from SARS-CoV-2 infection.

Authors:  Lorenzo A Calò; Luca Sgarabotto; Lucia Federica Stefanelli; Valentina Di Vico; Paul A Davis
Journal:  J Nephrol       Date:  2022-09-16       Impact factor: 4.393

Review 7.  The roles of cellular protease interactions in viral infections and programmed cell death: a lesson learned from the SARS-CoV-2 outbreak and COVID-19 pandemic.

Authors:  Martyna Majchrzak; Marcin Poręba
Journal:  Pharmacol Rep       Date:  2022-08-23       Impact factor: 3.919

8.  The Natural Products Withaferin A and Withanone from the Medicinal Herb Withania somnifera Are Covalent Inhibitors of the SARS-CoV-2 Main Protease.

Authors:  Shayantani Chakraborty; Dibyendu Mallick; Mausumi Goswami; F Peter Guengerich; Anindita Chakrabarty; Goutam Chowdhury
Journal:  J Nat Prod       Date:  2022-09-13       Impact factor: 4.803

9.  Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2.

Authors:  Nir Drayman; Jennifer K DeMarco; Krysten A Jones; Saara-Anne Azizi; Heather M Froggatt; Kemin Tan; Natalia Ivanovna Maltseva; Siquan Chen; Vlad Nicolaescu; Steve Dvorkin; Kevin Furlong; Rahul S Kathayat; Mason R Firpo; Vincent Mastrodomenico; Emily A Bruce; Madaline M Schmidt; Robert Jedrzejczak; Miguel Á Muñoz-Alía; Brooke Schuster; Vishnu Nair; Kyu-Yeon Han; Amornrat O'Brien; Anastasia Tomatsidou; Bjoern Meyer; Marco Vignuzzi; Dominique Missiakas; Jason W Botten; Christopher B Brooke; Hyun Lee; Susan C Baker; Bryan C Mounce; Nicholas S Heaton; William E Severson; Kenneth E Palmer; Bryan C Dickinson; Andrzej Joachimiak; Glenn Randall; Savaş Tay
Journal:  Science       Date:  2021-07-20       Impact factor: 63.714

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.